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ATAC = Anastrozole, Tamoxifen Alone or in Combination; IBIS = International Breast Intervention Study; OER = oestrogen receptor; P-1 = National
Surgical Adjuvant Breast and Bowel Project; SERM = selective oestrogen receptor modulation.
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Introduction
“The only true antiestrogen is no estrogen” was the state-
ment made by Terry Robinson during a discussion of a pre-
sentation entitled ‘Antiestrogens’ by Professor Cliff Emmens
at the Laurentian Hormone Conference in 1961 [1]. During
the past 40 years, however, a profound change has occurred
in the practice of cancer therapeutics, and medical oncology
has entered the era of molecular medicine.
Tamoxifen, a nonsteroidal anti-oestrogen, is established as
one of the first successful targeted therapies that has pre-
vented the deaths of 400,000 patients (Dr George Black-
ledge, AstraZeneca UK, personal communication, 2002)
with oestrogen receptor (OER)-positive tumours [2].
Remarkably, sufficient experience was accrued with
tamoxifen during the 1970s and 1980s to be able to ask
whether the medicine had worth in reducing the incidence
of breast cancer in high-risk premenopausal and post-
menopausal women. In 1998, Professor Bernard Fisher,
perhaps the most accomplished clinical trialist in the
world, reported the results from the first prospective,
placebo-controlled, breast cancer prevention trial
(National Surgical Adjuvant Breast and Bowel Project
[P-1]) [3] and the answer was “yes”. As a consequence of
the landmark accomplishment by the P-1 trial, tamoxifen is
now available in the United States for the reduction (50%)
of breast cancer incidence in premenopausal and post-
menopausal women at elevated risk [4].
I propose that the advance in progress with the early
results of the Anastrozole, Tamoxifen Alone or in Combina-
tion (ATAC) trial should be placed in context and exam-
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ined outside the single dimension of a ‘new and improved’
drug to be substituted for tamoxifen everywhere in medical
practice. In other words, the needs of the breast cancer
patients to stay alive, with fewer troublesome side effects,
are very different from the healthy woman at high risk for
breast cancer who needs to reduce her risk.
At the dawn of this new day what are the facts, how
should they be interpreted, and are there reasonable alter-
natives for chemoprevention that need to be considered?
The ATAC trial
The facts, simply stated, are as follows. The early results
(about 3 years) of an international adjuvant treatment
study, of 5 years of tamoxifen versus anastrozole versus
the combination of tamoxifen and anastrozole, show a
disease-free advantage for ‘no oestrogen’ (anastrozole)
versus an ‘anti-oestrogen’ (tamoxifen). The advantage is
shown by reducing recurrences in a huge population of
OER (or unknown) node-positive (30%) and node-
negative (70%) breast cancer patients [5]. Additionally,
‘no oestrogen’ is better than the ‘anti-oestrogen’ at reduc-
ing the incidence of contralateral (primary) breast cancer.
These encouraging antitumour results, coupled with a
reduced incidence of endometrial cancers and thrombo-
embolic disorders, suggest that aromatase inhibition
increases efficacy and reduces side effects. This dual
bonus is in fact historically much better than when tamoxifen
was first introduced. At that time, tamoxifen was found to
have fewer side effects but the same efficacy when com-
pared with the standard of care (diethylstilboestrol) for the
treatment of advanced breast cancer [6]. That is why
tamoxifen went forward with evaluation as an adjuvant
therapy. Clearly, if the early results of the ATAC trial prove
to be consistent over the next few years, a new day will
dawn for treatment. But it would be preferable, in the new
age of targeted therapies, to establish mechanisms for
these increased benefits first, so as not to be condemned
to relive the past.
Muddled mechanisms
The presence of the OER is critical for the mechanisms of
actions for both tamoxifen (blocking anti-oestrogen) and of
anastrozole (oestrogen biosynthesis inhibitor). Ideas that
mechanisms other than the OER could be responsible for
tamoxifen’s actions [7] have not stood the test of time [2].
This is why it has been so important to embrace this basic
concept of molecular medicine and to establish uniform
OER assays in the United Kingdom [8].
The OER remains the most effective target for breast
cancer therapeutics, and it is now imperative that we
advance further to determine why some patients respond
to anastrozole rather than to tamoxifen. The most probable
explanation is that the OER-positive tumour with ErbB1/2
positivity subverts the inhibitory action of tamoxifen. These
OER-positive, ErbB1/2-positive patients could be identi-
fied to establish whether anastrozole and tamoxifen are
equivalent in the patients with OER-positive, ErbB1/2-
negative tumours. This would support the preliminary
observation that tamoxifen is less effective than an aro-
matase inhibitor in ErbB1/2-positive and OER-positive
patients [9]. Interestingly enough, those patients in the
ATAC trial who were at greatest risk of recurrence also
received chemotherapy, but there was no difference
between tamoxifen and anastrozole treatment in this sub-
stantial subgroup [5]. This also suggests that ErbB2 has a
role.
Hazards of early reporting
The goal of the ATAC trial is to refine the established
breakthrough made by tamoxifen. Unfortunately, it is not
easy to be absolutely sure that early data will remain con-
sistent because only one-half of the required 5 years of
treatment has so far been given. Indeed, in an editorial in
the Lancet, Dr Radvin wondered how many participants
will elect to change to anastrozole alone, the safer, more
effective agent [10]. Although the primary goal of the
ATAC trial was to achieve a disease-free survival advan-
tage for anastrozole, it is hoped that a survival advantage
can be established.
If this situation sounds familiar, then that is because it is.
Substitute ‘P-1 prevention trial’ for ‘ATAC trial’ in the pro-
ceeding paragraph and you will recall the parallel. In 1998,
the P-1 prevention trial that was conducted in the United
States and Canada was reported at the American Society
for Clinical Oncology. Prearranged stop rules had been
invoked by the independent Endpoint and Safety Monitor-
ing Committee to release the results. In other words, there
was a prewritten undertaking to stop the trial if there was a
good or bad result of significance. Unlike the ATAC trial,
the followup in the P-1 trial was quite impressive: 37% of
13,688 volunteers had a median followup of longer than
5 years, and 67% of participants had a followup of
longer than 4 years. AstraZeneca played an appropriate
role by making tamoxifen available to all volunteers in the
placebo arm who wished to start tamoxifen as a chemo-
preventive. The Food and Drug Administration approved
tamoxifen in 1998. The question to be addressed now is
whether a single linear view of progress from a pioneering
anti-oestrogen to a drug that removes all oestrogen from a
woman’s body is the only dimension to be considered in
chemoprevention.
SERMs: a balance
John Lennon once wrote “Life is what happens to you
when you are making plans to do something else”.
Progress in medicine is more complex than the single
dimension of finding a replacement for tamoxifen because
other events of significance occur that should be evalu-220
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ated independently. Selective oestrogen receptor modula-
tion (SERM), a concept first recognised in the laboratory
in the mid-1980s [11,12], advanced the first agent, ralox-
ifene, to prevent osteoporosis with breast cancer and
endometrial safety. The new concept of SERM has
created an additional dimension in public health and
chemoprevention.
The Multiple Outcomes of Raloxifene Evaluation trial
showed an early (3 years) significant decrease in fractures
in osteoporotic postmenopausal women, but also showed
a beneficial reduction in both breast and endometrial
cancer. This was in 1998, and the dramatic findings for a
SERM, soon to be on the market, were presented at the
American Society for Clinical Oncology at the same
meeting as the P-1 trial, and were subsequently published
[13]. The STAR (Study of Tamoxifen and Raloxifene) trial
in the US is comparing the standard of care tamoxifen with
raloxifene in 22,000 postmenopausal women at high risk
for breast cancer. Having already evaluated tamoxifen and
raloxifene in randomised, placebo-controlled clinical
studies with in excess of 20,000 healthy women (P-1 trial
plus Multiple Outcomes of Raloxifene Evaluation trial), it
was not necessary to include a placebo arm because this
is guaranteed to have a higher incidence of breast cancer.
Clearly, women do not wish to exercise a wait-and-see
policy if risk reduction is proven possible. A high-risk
woman in America need only ask her doctor to prescribe
one or the other drug (tamoxifen or raloxifene) depending
on her preferences.
Chemoprevention and aromatase inhibitors
Tamoxifen still has a role in the chemoprevention of breast
cancer until proven otherwise by clinical trial. Specifically,
one-third of breast cancer occurs in premenopausal
women, and tamoxifen has an extraordinarily good
risk–benefit ratio in premenopausal women [3]. Anastro-
zole cannot be considered because it is effective only in
postmenopausal women. Tamoxifen has no adverse
effects on thromboembolic events or endometrial cancer,
and projected estimates of overall long-term benefits from
tamoxifen as a chemopreventive are highest for pre-
menopausal women [14]. It has already been stressed
[15], with tamoxifen coming off patent early next year in
the United States, that it will be the only option to provide
an extremely cost effective intervention for premenopausal
women at risk for breast cancer.
The issue to be considered for the future of chemopreven-
tion in postmenopausal women, therefore, is whether no
oestrogen will be superior to a balanced intervention with
a new generation of multifunctional medicines or SERMs
[16]. I was initially concerned (in the 1980s) that we might
prevent breast cancer with tamoxifen but increase the inci-
dence of the two major killers of women, osteoporosis and
coronary heart disease. The recognition of SERM action
advanced tamoxifen to become a preventive, but it more
importantly advanced the public health strategy of devel-
oping drugs to prevent osteoporosis and coronary heart
disease in postmenopausal women at risk and to prevent
breast cancer as a beneficial side effect [17].
I have never been anti oestrogen, but a clinical trial with an
aromatase inhibitor such as the International Breast Inter-
vention Study (IBIS) II trial should only consider the
recruitment of women at the highest risk. The possibility of
increasing the incidence of Alzheimer’s disease, osteo-
porosis and coronary heart disease in the general popula-
tion of healthy women seems too high a price to pay when
a balance with a new SERM may be best for public health.
This vision of progress in chemoprevention depends on
the outcome of the Study of Tamoxifen and Raloxifene trial
and the Raloxifene Use for the Heart trial [18], and most
importantly on the introduction of new SERMs [19] to
replace the aging agents tamoxifen and raloxifene.
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